

Contents lists available at ScienceDirect

International Journal of Medical Microbiology

journal homepage: www.elsevier.de/ijmm

Mini Review

Interaction of staphylococci with bone

John A. Wright, Sean P. Nair*

Division of Microbial Diseases, UCL Eastman Dental Institute, University College London, 256 Gray's Inn Road, London WC1X 8LD, UK

ARTICLE INFO

Keywords:
Staphylococcus aureus
 Small colony variants
 Bone infection
 Osteoblasts
 Osteoclasts
 Signalling

ABSTRACT

Staphylococci, in particular *Staphylococcus aureus*, are the predominant cause of bone infections worldwide. These infections are painful, debilitating and with the rise in antibiotic-resistant forms, increasingly difficult to treat. The growth in the number of prosthetic joint replacement procedures also provides new opportunities for these infections to take hold. Comprehending the mechanisms by which staphylococci interact with and damage bone is critical to the development of new approaches to meet this challenge. This review summarises current understanding of the mechanisms by which staphylococci infect and damage bone. We address the role of the inflammatory response to staphylococcal infection in disrupting the homeostatic balance of bone matrix deposition and resorption and thereby mediating bone destruction. A number of virulence factors that have been shown to contribute to bone infection and pathology are discussed, however no single factor has been defined as being specific to bone infections. Although traditionally considered an extracellular pathogen, there is increasing evidence that staphylococci are able to invade host cells, and that an intracellular lifestyle may facilitate long-term persistence in bone tissue, enabling evasion of antimicrobials and host immune responses. 'Small colony variant' strains, with mutations disabling the electron transport pathway appear particularly adept at invading and persisting within host cells, and exhibit enhanced antimicrobial resistance, and may represent a further complication in the treatment and management of staphylococcal bone disease.

© 2009 Elsevier GmbH. Open access under [CC BY-NC-ND license](http://creativecommons.org/licenses/by-nc-nd/3.0/).

Introduction

Bacteria of the genus *Staphylococcus* are the principal causative agents of two major types of infection affecting bone – septic arthritis and osteomyelitis, which involve the inflammatory destruction of joint and bone. These infections cause serious morbidity and are often difficult to manage (Berendt and Byren, 2004). The principal routes of infection for both osteomyelitis and septic arthritis are either haematogenous, resulting from bacteraemia; contiguous, when the infection is transmitted from local tissue; or direct, resulting from infiltration of bone, often following injury, surgery or implantation of a foreign body, such as joint replacement (Berendt and Byren, 2004; Ciampolini and Harding, 2000; Goldenberg, 1998; Lazzarini et al., 2004; Lew and Waldvogel, 2004). Infections may be acute or chronic and affect native joints, especially the hip and knee, or prosthetic joints, long bones, vertebrae and almost any other bone. Osteomyelitis of the foot is particularly common in diabetic patients (Berendt and Byren, 2004; Nade, 2003).

Septic arthritis is a joint disease typified by bacterial colonisation and rapid articular destruction (Levine and Siegel, 2003). Infiltration and growth of bacteria within the synovium results in inflammation with infiltration of leukocytes into the joint fluid (Goldenberg, 1998; Nade, 2003). The production of reactive oxygen species and host matrix metalloproteinases (MMPs), lysosomal enzymes and bacterial toxins contribute to the destruction of cartilage. This starts with degradation of host proteoglycans followed by collagen breakdown within hours of infection, and is mediated by polymorphonuclear leukocytes (Goldenberg, 1998; Nade, 2003; Shirliff and Mader, 2002; Stott, 2001). The containment of the inflammatory process within the joint results in increasing pressure, which impedes blood and nutrient supply to the joint exacerbating joint damage and facilitating destruction of cartilage and the synovium. Permanent destruction of articular cartilage and subchondral bone can occur rapidly, within just a few days (Shirliff and Mader, 2002).

Osteomyelitis describes a range of infections in which bone is colonized with microorganisms, with associated inflammation and bone destruction. Acute osteomyelitic foci are characterised by pus-forming inflammation at the site of microbial colonisation. Damage to bone matrix and compression and destruction of vasculature is also observed as the infection spreads to surrounding soft tissues, which can further exacerbate bone necrosis

* Corresponding author. Tel.: +44 207 915 1118; fax: +44 207 915 1127.
 E-mail address: snair@eastman.ucl.ac.uk (S.P. Nair).

(Lazzarini et al., 2004; Lew and Waldvogel, 2004) Sections of dead bone, known as sequestra, can form which may then detach to form separate infectious foci which, due to the lack of vasculature, are protected from immune cells and antibiotics (Lazzarini et al., 2004; Lew and Waldvogel, 2004). Such areas of dead, infected tissues that are inaccessible to antimicrobials or the immune response can lead to chronic persistence of the infection (Lazzarini et al., 2004).

The incidence of septic arthritis is between 2 and 10 in 100,000 in the general populace but may be as high as 30–70 per 100,000 in rheumatoid arthritis sufferers or recipients of prosthetic joints (Goldenberg, 1998; Nade, 2003; Stott, 2001) and is more common in children than adults, and in males rather than females (Levine and Siegel, 2003). Haematogenous osteomyelitis most frequently affects children and the elderly (Lew and Waldvogel, 2004) and in children, the incidence is typically between 1 in 5000 and 1 in 10,000 (Weichert et al., 2008). It has been argued that the incidence of haematogenous osteomyelitis is decreasing with an annual fall in childhood cases of 0.185 per 100,000 people recorded in Glasgow, Scotland between 1970 and 1997 (Blyth et al., 2001; Lazzarini et al., 2004; Weichert et al., 2008). Conversely, osteomyelitis resulting from direct infection is reportedly on the increase (Gillespie, 1990; Lazzarini et al., 2004). Local spread of infection from contiguous tissue to bone or direct infection can occur at any age, with foreign body implants a substantial risk factor (Lew and Waldvogel, 2004). The presence of an implant is particularly associated with chronic osteomyelitis, where antibiotic treatment is frequently ineffective, and removal of the implant and debridement are required (Ciampolini and Harding, 2000). Relapsing cases of osteomyelitis with several decades between episodes have been documented, and there are records of reactivation fifty or even eighty years after the initial infection (Ciampolini and Harding, 2000; Gallie, 1951; Greer and Rosenberg, 1993; Korovessis et al., 1991).

A broad range of bacterial species have been isolated in cases of septic arthritis and osteomyelitis. Pathogens cultured from septic joints include *S. aureus*, *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Serratia marcescens*, as well as *Salmonella*, *Neisseria*, *Aerobacter*, and *Bacteroides* species (Nade, 2003; Shirliff and Mader, 2002). *Staphylococcus* and *Streptococcus* spp., *Haemophilus influenzae*, *E. coli*, *P. aeruginosa*, *Salmonella* and *Mycobacterium* spp. are all potential causes of osteomyelitis (Bennet and Bennet, 2006; Lazzarini et al., 2004; Lew and Waldvogel, 1997, 2004). *S. aureus* is the most commonly identified pathogen in both conditions, by a substantial margin, regardless of type or route of infection (Ciampolini and Harding, 2000; Goldenberg, 1998; Lew and Waldvogel, 2004).

Staphylococcus, principally *S. aureus*, accounts for between 37% and 67% of septic arthritis isolates in studies from a range of nations (Al Arfaj, 2008; Dubost et al., 2002; Goldenberg, 1998; Ryan et al., 1997). Coagulase-negative staphylococci are less commonly isolated from arthritic joints, representing between 3% and 16% of *Staphylococcus* cultures (Al Arfaj, 2008; Dubost et al., 2002; Ryan et al., 1997). Studies of osteomyelitis in several developed countries over the past decade have identified *S. aureus* in 38% to 67% of culture-positive cases. Coagulase-negative staphylococci were identified in 5% to 15% of culture-positive patients (Arnold et al., 2006; Blyth et al., 2001; Grammatico et al., 2008; Karwowska et al., 1998). Surveillance data from the Health Protection Agency on surgical site infections in the U.K. between 1997 and 2005 found *S. aureus* to be the causative agent in 41.4% of hip prosthesis, 33.5% of knee prosthesis, 53% of open reduction of bone fracture and 59.1% of hip hemiarthroplasty infections. Coagulase-negative staphylococci accounted for 15.1%, 20.7%, 7.5% and 6.3% of these infections, respectively (U.K. Health Protection

Agency, 2008). *S. epidermidis* is the most common coagulase-negative *Staphylococcus* species in many types of infection, including osteomyelitis and infection of prosthetic joints, but other species, including *Staphylococcus simulans*, *Staphylococcus hominis*, *Staphylococcus capitis*, *Staphylococcus caprae* and *Staphylococcus lugdunensis* have all been reported (Greig and Wood, 2003; Lang et al., 1999; Murdoch et al., 1996; Vallianou et al., 2008).

Clearly *S. aureus*, and to a lesser extent other staphylococci, are pathogens of major importance in skeletal infections. The number of joint replacement procedures is increasing: 220,000 hip replacements were performed in the USA in 2003, a 38% rise from 1996, with numbers projected to rise to 572,000 by 2030. Total knee replacements reached 418,000 in 2003 and are expected to undergo a similar rise, especially in light of an aging population (Lee and Goodman, 2008). In cases of septic arthritis antibiotic therapy is frequently effective if applied rapidly, appropriately and in combination with joint drainage (Shirliff and Mader, 2002). Osteomyelitis is, however, often refractory to antibiotic treatment, a problem exacerbated by the increasing levels of antibiotic resistance amongst *Staphylococcus* spp. This is complicated further by the emergence of particularly persistent, antibiotic-resistant 'small colony variant' forms that may be selected for by certain current treatment regimens (Ciampolini and Harding, 2000; Henderson and Nair, 2003; von Eiff et al., 1997a). Staphylococcal bone infections are thus likely to be a continuing and probably increasing problem, and understanding of the interaction of these pathogens with bone is central to development of the novel therapeutic strategies required to treat increasingly antibiotic-resistant and persistent infections.

Genomic features of staphylococci associated with bone infections

A number of studies have attempted to identify an association between the possession of certain virulence genes by *S. aureus* and invasive disease. Thus Peacock et al. (2002) suggested that the possession of certain combinations of virulence factor genes is associated with invasive disease, and increased severity of infection following examination of a panel of 334 *S. aureus* isolates by PCR. The isolates comprised those from 179 healthy patients, 94 hospital-acquired isolates and 61 community-acquired isolates. Seven putative virulence genes, including the adhesin genes *fnbA* and *cna*, the toxin genes *sej*, *eta* and *hlg*, and *icaA*, which is involved in biofilm production, were found to be associated with invasive isolates. The association with specific types of invasive infection was not examined and indeed the small number of isolates examined in this study would have precluded such an analysis (Peacock et al., 2002). The genes for the fibronectin-binding proteins *fnbA* and *fnbB* have been reported to be present in 98% and 99% of clinical isolates, respectively, from a range of orthopaedic associated infections, whereas the *cna* gene, encoding the collagen-binding protein was identified in just 46% of isolates (Arciola et al., 2005). Another study by Peacock et al. (2000) found the prevalence of both *fnbA* and *fnbB* genes, as opposed to just one of the two, to be significantly higher in invasive isolates than in 'carriage' strains in a panel of 163 strains, which included septic arthritis and osteomyelitis isolates. Genes encoding Pantone-Valentine leukocidin were found to be present in 59 of 89 *S. aureus* isolates from cases of acute haematogenous osteomyelitis. The presence of *pvl* genes is associated with an increased risk of severe infection requiring intensive care, bacteraemia and more severe systemic inflammation (Bocchini et al., 2006; Sdougkos et al., 2007). However, one of the problems with the above studies is that it is unclear how representative

these strain collections are of those isolates carried in other establishments and regions across the world, since strain typing was not reported.

Strain typing studies of *S. aureus*, using multilocus sequence typing (MLST) and comparative genomic microarray hybridizations have so far failed to identify any specific clonal lineages associated with invasive disease (Feil et al., 2003; Lindsay et al., 2006). However, these studies did not use a collection of isolates from specific invasive diseases and therefore do not rule out the possibility that specific lineages or genes are associated with specific types of infection, such as osteomyelitis or septic arthritis. To date, the only genome comparison study relevant to *S. aureus* bone infections has been done using comparative genome microarray hybridisations of the *S. aureus* UAMS-1 strain, isolated from an osteomyelitis patient, with a range of genome sequenced strains (Cassat et al., 2005). These authors found variations in the complement of adhesin, toxin, exoenzyme and regulatory genes. Although it is not possible to draw general conclusions about association with bone infection from characterisation of a single strain, the presence of *fnbA*, but not *fnbB* or the bone sialoprotein-binding gene *bbp*, in UAMS-1 suggest that *fnbB* and *bbp* are dispensable for bone infection, at least in certain genetic backgrounds. Thus at this juncture there is a lack of evidence to support or disprove an association between specific *S. aureus* lineages or specific genomic features and the pathogenesis of bone infections.

Bone as a target organ

In terrestrial vertebrates mature bone is made up of dense surface plates of bone, known as the cortices, and within these is a network of bone struts oriented to oppose loading forces, known as trabecular bone. Trabecular bone is typically replaced every 3–4 years, with the denser cortical bone taking over a decade to replace in adults (Blair, 1998). This process of continual remodelling is required to remove old bone and microfractures to ensure bone integrity and mineral homeostasis (Vaananen and Laitala-Leinonen, 2008). The skeleton is a dynamic organ system, in a state of perpetual turnover which is continually remodelled by the actions of two cell types (Henderson and Nair, 2003). Osteoblasts are responsible for the deposition of bone matrix; they are found on bone surfaces and are derived from mesenchymal osteoprogenitor cells. These cells secrete osteoid, a mixture of bone matrix proteins primarily made up of type I collagen (over 90%), proteoglycans such as decorin and biglycan, glycoproteins such as fibronectin, osteonectin and tenascin-C, osteopontin, osteocalcin and bone sialoprotein, oriented along stress lines (Blair, 1998; Mackie, 2003). Osteoblasts are also thought to facilitate the mineralization of bone matrix, whereby hydroxyapatite, $[\text{Ca}_3(\text{PO}_4)_2]_3 \cdot \text{Ca}[\text{OH}]_2$, crystals form, making up around 90% of bone matrix (Blair, 1998; Mackie, 2003). It is thought that 'nucleators' are required to instigate mineralisation, and phosphate-containing matrix proteins like bone sialoprotein and osteopontin are likely to play such a role (Henderson and Nair, 2003; Mackie, 2003; van de Lest and Vaandrager, 2007). Osteoblasts also produce tissue non-specific alkaline phosphatase (TNAP) which cleaves phosphate esters to liberate free inorganic phosphate, which is key to the process of mineralisation (van de Lest and Vaandrager, 2007). Osteoblasts are not terminally differentiated, and some may form osteocytes and become implanted in the bone matrix, eventually ceasing the secretion of osteoid, whilst others undergo apoptosis (Blair, 1998; Mackie, 2003). Osteocytes are also involved in bone maintenance, detecting stress within the bone through mechanosensitive mechanisms located in extensive cellular projections, called canaliculi, that interconnect osteocytes (van de

Lest and Vaandrager, 2007). Osteocytes are thought to respond to mechanical stress by undergoing apoptosis, leading to osteoclast recruitment and differentiation, possibly by alterations in the levels of soluble factors produced by the osteocyte. Candidates include transforming growth factor β (TGF- β), which may suppress osteoclastogenesis when produced by healthy osteocytes (Henriksen et al., 2009; Matsuo and Irie, 2008).

The opposing action of bone matrix removal is performed by osteoclasts, multinucleate cells that are derived from the macrophage-monocyte lineage. These cells express large quantities of a vacuolar-type H^+ -ATPase on their cell surface, along with chloride channel 7 (ClC 7) enabling localised hydrochloric acid secretion into a closed compartment, known as the resorption lacuna, and subsequent solubilisation of bone mineral (Blair et al., 1989; Blair, 1998; Kornak et al., 2001; Vaananen and Laitala-Leinonen, 2008). The cell is attached to the bone matrix by a sealing zone membrane to create this compartment, and fusion of acidified vesicles with the plasma membrane contributes further to acid release (Vaananen and Laitala-Leinonen, 2008). Following mineral solubilisation, proteolysis of bone matrix proteins is then possible. Cathepsin K is centrally involved in degradation of bone matrix, it is highly expressed by osteoclasts and digests substrates such as collagen and osteonectin (Bossard et al., 1996; Drake et al., 1996). Evidence from knock-out mouse and selective inhibitor experiments indicates that cathepsin L, and MMPs also play a role in degrading bone matrix (Everts et al., 2006). Osteoclasts also secrete acid phosphatases, such as tartrate-resistant acid phosphatase (TRAcP), which is used as an osteoclast marker and is activated by cathepsin K cleavage (Blair et al., 1989; Blair, 1998; Ek-Rylander et al., 1991; Ljusberg et al., 2005). TRAcP is able to generate reactive oxygen species in addition to having phosphatase activity (Hayman and Cox, 1994). The exact cellular function of TRAcP in bone resorption is not well understood, but serum TRAcP levels correlate with bone-resorptive activity, and TRAcP-deficient mice exhibit reduced osteoclastic bone resorption and increased bone mineralization (Angel et al., 2000; Hayman et al., 1996; Nesbitt and Horton, 1997; Salo et al., 1997).

The balance of activity between these two cell types is crucial to maintaining the proper homeostasis of bone turnover, and any shift in the relative levels of osteoblast and osteoclast activity can result in bone pathology (Henderson and Nair, 2003). Infection with a pathogen such as *S. aureus* is capable of stimulating such a shift, mediated in part by induction of an inflammatory response. There is intimate interaction between the two cell types, with osteoblasts interpreting the majority of extracellular signals and subsequently modulating osteoclast differentiation and function (Henderson and Nair, 2003; Matsuo and Irie, 2008). Interaction between the RANK (receptor activator for nuclear factor κB) receptor, expressed by osteoclast precursors, and its cognate ligand, RANKL, expressed by osteoblasts is essential for osteoclastogenesis (Matsuo and Irie, 2008). RANKL is a homotrimeric protein displayed on the membrane of osteoblasts, although it may be secreted following cleavage by MMPs 7 or 14, or ADAM (a disintegrin and metalloprotease domain) (Boyce and Xing, 2008; Hikita et al., 2006; Lynch et al., 2005). Suppression of MMP 14-mediated secretion enhances osteoclastogenesis (Boyce and Xing, 2008; Hikita et al., 2006). The RANK receptor is a homotrimeric transmembrane protein belonging to the tumour necrosis factor (TNF) receptor superfamily. Following binding of RANKL to RANK, TRAF (TNF receptor-associated factor) adaptor proteins are recruited, with binding sites for TRAF2, TRAF5 and TRAF6 all present on RANK (Kim et al., 1999; Wada et al., 2006). TRAF6 seems to play a central role in RANK-mediated osteoclast formation, and mice deficient in TRAF6 are osteopetrotic (Lomaga et al., 1999) whereas TRAF2 and TRAF5 are relatively marginal players in osteoclastogenesis (Kanazawa et al., 2003; Kanazawa

and Kudo, 2005). Signalling via RANK, and these adaptor proteins, activates a number of transcription factors, including NF κ B (nuclear factor κ B), AP-1 (activator protein 1) and NFATc1 (nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1) which drive osteoclast differentiation (Matsuo and Irie, 2008; Wada et al., 2006). Osteoprotegerin (OPG) is an endogenous inhibitor of RANKL signalling, functioning as a decoy receptor that binds to RANKL and prevents its association with RANK (Wada et al., 2006; Yasuda et al., 1998).

Inflammation in bone infection

A number of host cytokines play a significant role in the pathogenesis of osteomyelitis, and there is strong evidence that production of these cytokines is induced by staphylococcal infection of bone, and that they directly contribute to bone destruction. In particular, the inflammatory cytokines tumour necrosis factor α (TNF α), interleukin 1 (IL-1) and IL-6 seem to be especially important in bone physiology and pathology (Kwan et al., 2004). In patients with acute osteomyelitis, plasma levels of TNF α , IL-1 β (the secreted form of IL-1) and IL-6 are all elevated (Evans et al., 1998; Klosterhalfen et al., 1996). High levels of IL-1 β , IL-6 and TNF α are also found in the synovial fluid of patients with septic arthritis (Osiri et al., 1998; Saez-Llorens et al., 1990). Interestingly, specific polymorphisms in the IL-1 α and IL-6 genes have recently been found to be associated with an increased risk of osteomyelitis in the Greek population (Tsezou et al., 2008).

A number of animal models of *S. aureus* osteomyelitis reveal that bone infection can lead to elevated levels of these cytokines both locally and systemically. Increased levels of IL-1 β have been measured in the tibiae of 22-month-old rats experimentally implanted with *S. aureus*-infected needles, and the same animals have increased circulating levels of IL-6 (Garcia-Alvarez et al., 2009). In a murine osteomyelitis model, bone levels of IL-1 β and IL-6 are significantly increased in the early post-infection period, with TNF α rising later during the infection (Yoshii et al., 2002). The local source of these cytokines is not fully clear. Production of IL-1 β can be induced in human osteoblast-like cell lines by a variety of stimuli, including TNF α (Pivrotto et al., 1995). However, infection of primary mouse osteoblasts with *S. aureus* results in increased transcription, but not increased protein synthesis or secretion of IL-1 β (Marriott et al., 2002). TNF α is detectable only at low levels in human osteoblasts derived from mesenchymal stem cells and the osteosarcoma cell line MG63 (Bu et al., 2003). Infiltrating immune cells may therefore be a more likely source of IL-1 β and TNF α in bone in response to infection (Bost et al., 1999; Ishimi et al., 1990; Marriott et al., 2002; Mundy, 1991; Robinson et al., 2007). IL-6 however, is produced by osteoblasts in response to a variety of signals, including infection with *S. aureus* (Bost et al., 1999; Ishimi et al., 1990).

These cytokines have potent effects on the process of bone remodelling, and are strongly implicated in the pathology of osteomyelitis. Cell culture models support the view that IL-1 and TNF α stimulate the proliferation and differentiation of osteoclast progenitors into mature osteoclasts in the presence of osteoblasts (Mundy, 1991; Pfeilschifter et al., 1989; Tokukoda et al., 2001). TNF α and IL-1 β also stimulate osteoclast-mediated bone resorption, a process which may also require the presence of osteoblasts (Azuma et al., 2000; Taubman and Kawai, 2001; Thomson et al., 1987). Similarly, IL-6 increases bone resorption activity and osteoclast number in cultured mouse calvariae, and stimulates osteoclast differentiation in the presence of osteoblasts (Ishimi et al., 1990; Kotake et al., 1996). In vivo, local administration of IL-1 and TNF antagonists in a non-human primate model of periodontitis results in significant reduction of osteoclast forma-

tion and bone destruction (Assuma et al., 1998). Intravenous administration of TNF α and IL-1 in mice stimulates bone resorption in a dose-dependent fashion (Konig et al., 1988), and deletion of the murine IL-1R, TNF-R1 and TNF-R2 receptors and of caspase-1 significantly decreases osteoclast number and the area of bone resorption in calvariae following lipopolysaccharide (LPS) injection (Chiang et al., 1999).

IL-1 β and TNF α also inhibit the differentiation of mesenchymal stem cells into osteoblast-like cells, and suppress the accompanying mineralisation and increased expression of alkaline phosphatase and procollagen I genes, although only TNF α inhibits osteonectin and osteopontin gene expression (Lacey et al., 2008). TNF α also decreases production of type I collagen and osteocalcin, and of alkaline phosphatase in a variety of osteoblast cell culture and bone tissue explant models, thereby reducing matrix deposition and mineralisation (Canalis, 1987; Centrella et al., 1988; Li and Stashenko, 1992; Nanes et al., 1989, 1991; Nanes, 2003; Smith et al., 1987).

Surface-associated material (SAM) from *S. aureus* stimulates bone resorption and osteoclast formation, and blockade of IL-1 or TNF α signalling completely abolishes this bone resorption activity. Neutralisation of TNF α and IL-6 fully abolishes SAM-stimulated osteoclastogenesis, with antagonism of IL-1 having only a partial effect (Meghji et al., 1998; Nair et al., 1995). The effect of this SAM on osteoclast formation and stimulation of resorption does not require co-culture with osteoblasts, and does not require RANKL signalling (Lau et al., 2006). *S. epidermidis* surface material can also induce bone resorption, by a mechanism that is strongly dependent on TNF α and, to a lesser extent, IL-1 (Meghji et al., 1997).

Induction and release of these cytokines in response to pathogen-associated molecules involves two main classes of pattern recognition receptors (PRRs), the Toll-like receptors (TLRs) and NOD-like receptors (NLRs). The production of TNF α and IL-6 by murine macrophages in response to *S. aureus* cell wall preparations is dependent on TLR2, and TLR2-deficient mice exhibit reduced survival of intravenous *S. aureus* infections compared to wild-type counterparts (Takeuchi et al., 1999, 2000). Signalling through TLRs, in response to microbial ligands such as LPS, 'primes' the cell for IL-1 β production by inducing expression of the inactive, pro-form of the cytokine (Creagh and O'Neill, 2006; Kahlenberg et al., 2005). IL-1 β is synthesised as a 31-kDa precursor molecule, and is processed to produce a 17-kDa active molecule by caspase-1. Caspase-1 activation, and subsequent processing and release of active IL-1 β involves assembly of a multiprotein complex known as the inflammasome. This complex consists of caspase-1, the adaptor protein ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain (CARD)) and one of several NLR proteins, of which four are known to associate with inflammasomes (Ting et al., 2008). Each NLR responds to different activating signals, and although the exact recognition steps remain to be elucidated, reported stimuli include flagellin, anthrax lethal toxin, and muramyl dipeptide (Boyden and Dietrich, 2006; Faustin et al., 2007; Franchi et al., 2006; Miao et al., 2006). A broad range of stimuli for NLRP3 (NLR family pyrin domain containing 3) have been reported, including *S. aureus*. Although NLRP3 and ASC are essential for IL-1 β secretion by murine macrophages in response to *S. aureus*, the stimulating signal is as yet unknown, and deletion of the α -, β - and γ -toxins does not perturb production of the cytokine (Mariathasan et al., 2006; Ting et al., 2008). The inflammasome is involved in cell death in response to bacterial invasion (Marriott et al., 2002; McCall et al., 2008) and although invasion of murine osteoblasts by *S. aureus* induces apoptosis, it is not established whether the inflammasome is involved (Tucker et al., 2000).

The major signal transduction events following binding of IL-1 and TNF to their respective receptors are shown in Fig. 1.




Fig. 1. Schematic diagram of IL-1 and TNF signal transduction events. (A) IL-1 binding to IL-1RI results in recruitment of the IL-1 receptor accessory protein IL-1RAcP, which form a complex that, via the intracellular Toll/IL-1 receptor (TIR) domains of the two receptor molecules, engages the MyD88 (myeloid differentiation factor 88) adaptor protein (Arend et al., 2008; Dinarello, 2009; Verstrepen et al., 2008). MyD88 binding initiates phosphorylation of IRAK-4 (interleukin-1 receptor-associated kinase 4), IRAK-2 and IRAK-1. IRAK-1 recruits TRAF6 and these two proteins localise to the cell membrane where they associate with TAK1 (TGF- β -activated kinase 1), TAB1 (TAK1-binding protein) and TAB2. The TAK1/TAB1/TAP2/TRAF6 complex translocates to the cytosol where TRAF-6 is poly-ubiquitinated and TAK1 is subsequently phosphorylated, and activates NF- κ B, p38 MAPK and JNK. The MyD88 adaptor molecule and downstream signalling events are common to most Toll-like receptors (TLRs), and, via TRAF6, this pathway also converges with RANKL signalling. (B) Engagement of the homotrimeric TNF-R1 receptor by TNF enables recruitment of TRADD (TNF-R1 associated death domain protein) via homotypic death domain interactions. TRADD associates with itself, TRAF2 and RIP1 (receptor-interacting protein 1) and with TRAF5. TNF-R2 is able to directly associate with TRAF2, independently of TRADD. TRAF2 auto-poly-ubiquitinates and ubiquitinates RIP1. Poly-ubiquitination of RIP1 then leads to the recruitment of TAK1, through interactions with TAB1, TAB2 and TAB3, again leading to NF- κ B, p38 MAPK and JNK activation (Bradley, 2008; Verstrepen et al., 2008).

Signalling in response to both cytokines leads to eventual activation of the NF κ B transcription factor and JNK (c-Jun N-terminal kinase) and p38 MAPK (mitogen-activated protein kinase) signalling (Arend et al., 2008; Dinarello, 2009). Studies with knockout mice have shown that at least one of the p50 or p52 NF κ B subunits is required for IL-1-induced osteoclast formation and resorptive activity, indicating that much of the osteoclastogenic activity of IL-1 is dependent on NF κ B (Xing et al., 2003). TNF α binds to two receptors, TNF type I (TNF-R1) and type II (TNF-R2) receptor which differ in their signalling mechanisms although there is substantial signalling crosstalk between the two receptors (Aggarwal, 2003; Wajant et al., 2003). Interestingly, the *S. aureus* virulence factor protein A, in addition to possession of immunoglobulin G-binding activity, is able to bind to the TNF-R1 receptor and stimulates downstream signalling and inflammation (Gomez et al., 2004). TNF α mediates the osteoclastogenic activity of RANKL. TNF α production by osteoclast progenitors is induced by RANKL and stimulates osteoclast differentiation in an autocrine manner (Zou et al., 2001). Fig. 2 shows an overview of the signal transduction events following IL-6 binding to its receptor. Signal transduction involves the activation of Janus family (JAK) tyrosine kinases and subsequent phosphorylation and activation of STAT (signal transducers and activators of transcription) family transcription factors (Kwan et al., 2004). IL-6 mediates bone resorption indirectly, and has no effect on isolated osteoclasts and IL-6 induction of osteoclastogenesis is dependent on the expression of the IL-6 receptor by osteoblasts, but not osteoclast progenitors (Hattersley et al., 1988; Kwan et al., 2004; Udagawa et al., 1995).

It is clear that these cytokines have a prominent role in modulating bone turnover, and perturbation of their levels can have profound effects on this process. Although some mechanistic details are currently lacking, there is strong evidence that *S. aureus* infection of bone initiates local and systemic production of TNF α , IL-1 and IL-6 via host PRRs. Elevated levels of these cytokines then

shift the homeostatic balance of bone turnover, increasing osteoclast differentiation and bone resorption and diminishing osteoblast-mediated bone matrix production and mineralisation, thereby driving bone destruction.

Staphylococcal invasion of bone cells

In addition to staphylococcal induction of inflammatory mediators that modulate the actions of osteoblasts and osteoclasts, bacteria of this genus are involved in more direct interactions with bone cells. Invasion and persistence of *S. aureus* in 'non-professional phagocytic' host cells in vitro has been described for many different cell types, including epithelial cells, endothelial cells and keratinocytes (Garzoni and Kelley, 2009; Kintarak et al., 2004). In cell culture systems, *S. aureus* is able to invade cultured osteoblasts from murine, human and embryonic chick sources, and *S. epidermidis* is also able to invade and grow within cultured osteoblasts (Ellington et al., 1999; Hudson et al., 1995; Jevon et al., 1999; Khalil et al., 2007; Reilly et al., 2000). Electron microscopy has demonstrated the presence of bacteria within osteoblasts and osteocytes of embryonic chicks following injection with *S. aureus*, indicating that internalisation by bone cells also occurs in vivo (Reilly et al., 2000). Intracellular bacteria inside osteoblasts and osteocytes in a patient with recurrent, long-term osteomyelitis of the fibula have been visualised by light and electron microscopy, although the species was unfortunately not determined (Bosse et al., 2005). More recently Stoodley et al. (2008), have demonstrated *S. aureus* biofilms in an infected total joint arthroplasty. Although not reported in this paper the authors also identified *S. aureus* within host cells (personal communications, Stoodley). Thus the suggestion that internalisation of *S. aureus* by bone cells in vivo provides a protective niche for the bacterium, where it is shielded from immune effector mechanisms and antibiotics, may help to explain persistent cases




Fig. 2. Schematic diagram of IL-6 signalling events. IL-6 specifically binds to IL-6 receptor α (IL-6R α), and recruits a homodimer of the gp130 signal-transducing protein (Naugler and Karin, 2008). This in turn leads to association of the JAK kinases JAK1, JAK2 and TYK2 with gp130, and the autophosphorylation of these kinases (Heinrich et al., 2003). JAK1 is of particular importance in IL-6 signalling, and cells deficient in this kinase exhibit substantial signalling impairment (Guschin et al., 1995; Heinrich et al., 2001; Rodig et al., 1998). Following JAK activation, gp130 is phosphorylated on multiple tyrosine residues, enabling recruitment and phosphorylation of STAT family transcription factors. STAT3 is the major transcription factor acting downstream of IL-6 signalling, and dimerises upon phosphorylation and translocates to the nucleus to activate transcription of an array of target genes (Li et al., 2002; Naugler and Karin, 2008). IL-6 also activates the MAPK pathway, via JAK phosphorylation of SHP2 (SH2 domain-containing protein-tyrosine phosphatase). SHP2 is thought to recruit either the Grb2-SOS (growth factor receptor-bound protein/Son of Sevenless) complex and/or Gab1 (Grb2-associated binder 1) to gp130. Recruitment of SOS then enables activation of Ras and subsequently the MAPK (mitogen-associated protein kinase) pathway, although the importance of this pathway is currently unclear (Heinrich et al., 2003; Naugler and Karin, 2008).

of osteomyelitis. However, the true importance of intracellular staphylococci in clinical osteomyelitis has yet to be established (Henderson and Nair, 2003).

S. aureus requires fibronectin-binding proteins (FnBPs) expressed on the surface of the bacterium to enable uptake by osteoblasts, and many other cell types (Ahmed et al., 2001; Garzoni and Kelley, 2009; Sinha et al., 1999). These proteins belong to a group of adhesins known as MSCRAMMs (microbial surface components recognising adhesive matrix molecules), which bind a range of extracellular matrix proteins including fibronectin, fibrinogen, collagen, elastin and bone sialoprotein (Hauck and Ohlsen, 2006). Mutants deficient in the two FnBPs, FnBPA and FnBPB invade host cells very poorly (Ahmed et al., 2001; Sinha et al., 1999). Invasion is dependent on fibronectin binding by these proteins, and on the host cell integrin $\alpha 5\beta 1$ receptor (Dziewanowska et al., 1999; Fowler et al., 2000; Sinha et al., 1999). *S. aureus* binds to fibronectin via FnBPs displayed on the bacterial surface, and fibronectin serves as a bridging molecule to the integrin $\alpha 5\beta 1$ which acts as a “phagocytic” receptor (Sinha et al., 1999). Alternative uptake mechanisms do exist in certain cell types, however, as *S. aureus* is still able to invade primary keratinocytes in the absence of FnBPs and uptake is not inhibited by blockade of integrin $\alpha 5\beta 1$ binding to fibronectin (Kintarak et al., 2004). The mechanism of invasion also differs between *S. aureus* and *S. epidermidis* and the latter does not gain entry via the fibronectin-integrin $\alpha 5\beta 1$ mechanism (Khalil et al., 2007). The level of expression of the alternative sigma factor, σ^B , affects *fnbA* expression and the fibronectin binding ability of *S. aureus* strains and correlates with the level of internalisation of bacteria by osteoblasts suggesting that σ^B -mediated up-regulation of FnBP expression may facilitate invasion (Mitchell et al., 2008; Nair et al., 2003).

Integrin $\alpha 5\beta 1$ -mediated uptake of *S. aureus* requires remodelling of the actin cytoskeleton (Agerer et al., 2005). The integrin-linked kinase, ILK, provides a link between $\alpha 5\beta 1$ and the

cytoskeleton, and interacts with the cytoplasmic domains of β integrins and is subsequently activated. ILK activity is required for internalisation of *S. aureus* by epithelial cells (Wang et al., 2006). Recruitment of focal adhesion proteins, including the adaptor protein paxillin and the focal adhesion kinase, FAK, follows (Boulter and Van Obberghen-Schilling, 2006). Upon infection of HEK293T cells with *S. aureus* there is also recruitment of focal adhesion proteins, such as tensin, zyxin and vinculin to the site of bacterial attachment. FAK is recruited and tyrosine phosphorylated, and FAK-deficient cells are able to internalise *S. aureus* much less efficiently. Phosphorylation of downstream substrates of FAK, including cortactin, which is involved in actin cytoskeletal organisation, occurs during invasion, and interference with cortactin also reduces internalisation. So, signalling downstream of the integrin $\alpha 5\beta 1$ receptor, involving ILK and FAK, is important for *S. aureus* invasion, at least in certain cell types (Agerer et al., 2005; Wang et al., 2006). Fig. 3 shows an overview of some of the events involved in the internalisation of *S. aureus* by host cells.

Physical contact between *S. aureus* and osteoblasts induces host cell expression of tumour necrosis factor apoptosis inducing ligand (TRAIL) (Alexander et al., 2003). TRAIL is a member of the TNF cytokine family, and binds to two death domain-containing receptors, TRAIL receptors 1 and 2, which once activated recruit the FADD (Fas-associated protein with death domain) adaptor protein which in turn activates caspases 8 and –10 and commits the cell to an apoptotic pathway (Mahalingam et al., 2009). TRAIL produced by *S. aureus*-infected osteoblasts induces caspase-8 activation and apoptosis in cultured osteoblasts (Alexander et al., 2003). Uninfected osteoblasts cultured alongside infected cells also express TRAIL (Reott Jr., et al., 2008). TRAIL can induce apoptosis in human osteoclasts via TRAIL receptor 2, and also inhibits osteoclast differentiation (Colucci et al., 2007; Zauli et al., 2004). It is therefore possible that apoptosis of bone cells infected




Fig. 3. Schematic diagram of some of the signalling events involved in invasion of 'non-professional phagocytic' host cells by *S. aureus*. FnBPs expressed on the bacterial surface bind to fibronectin molecules in the extracellular matrix, which form a bridge with integrin $\alpha 5 \beta 1$ on the host cell membrane (Dziewanowska et al., 1999; Fowler et al., 2000; Sinha et al., 1999). Ligation of this complex to the integrin receptor causes receptor clustering and subsequent activation of ILK, via interaction with the $\beta 1$ subunit (Wang et al., 2006). There is subsequent recruitment of paxillin and FAK and downstream phosphorylation of cortactin leading to remodelling of the actin cytoskeleton to enable bacterial uptake (Agerer et al., 2005). The focal adhesion proteins zyxin, vinculin and tensin are also recruited to the site of bacterial uptake, the latter two potentially via interactions with paxillin and FAK, respectively (Agerer et al., 2005).

with *S. aureus*, and potentially of neighbouring uninfected cells may contribute to bone loss in osteomyelitis (Henderson and Nair, 2003).

Growing experimental support indicates that staphylococcal invasion of osteoblasts, most likely via the FnBP-fibronectin-integrin $\alpha 5 \beta 1$ bridging mechanism in the case of *S. aureus*, may play a role in the pathogenesis of bone infections. This intracellular location may provide a protected environment for bacteria, aiding prolonged persistence by enabling evasion of antimicrobials and host immune mechanisms and possibly contributing to bone damage by inducing apoptosis of infected cells.

Staphylococcal virulence determinants

A number of animal models of bone implant infection, osteomyelitis and septic arthritis have been developed which have enabled the role of specific virulence factors in infections to be determined. As mentioned at the outset there are a number of routes of bone infection, i.e. haematogenous, contiguous and direct infection of bone, and models have been developed to mimic each of these routes of infection. This is important since the range of environments experienced by the bacterium differs for each route and hence the virulence factors that are involved in pathology may be different for each route of infection. The septic arthritis model developed by Tarkowski and colleagues (Bremell

et al., 1991, 1992; Tarkowski et al., 2001) in conjunction with defined isogenic mutants deficient in one or more virulence determinants, or with neutralising antibodies to virulence factors has proven to be particularly useful in elucidating the role of specific virulence determinants and host factors in bone infections. This model has shown that there is a plethora of virulence determinants involved in *S. aureus* septic arthritis (Table 1) some of which are also involved in osteomyelitis (Table 1). However, there is some controversy in this area because whilst the murine septic arthritis model is well established and standardised a number of different models have been developed for osteomyelitis and the relevance of specific virulence factors to bone implant infections or osteomyelitis appears to be dependent on the particular model used. For example the collagen adhesin Cna has been shown to contribute to osteomyelitis by some workers (Elasri et al., 2002) but not by others (Johansson et al., 2001) and has been reported not to be important in orthopaedic device infections (Darouiche et al., 1997). The role of FnBPs has not been directly assessed in a model of osteomyelitis, but comparison of *S. aureus* strains with and without fibronectin-binding activity in a mouse osteomyelitis model suggests that fibronectin-binding strains may give rise to more severe bone infections (Johansson et al., 2001). In the septic arthritis model, *S. aureus* *fnbA fnbB* mutants show no reduction in severity of arthritis, in contrast with *clfA clfB* mutants lacking the fibrinogen-binding clumping factors. However, the presence of the *fnb* genes results in greater weight loss and mortality, as well as higher serum levels of IL-6,

Table 1
Virulence determinants which have been demonstrated to play a role in the pathology of experimental *S. aureus* bone infections. Most studies have utilised the murine model of septic arthritis.

| Virulence determinant | Model | Reference |
|-----------------------------------------------------------------------------------|-------|--------------------------------------------------------------------------------|
| Accessory gene regulator (<i>agr</i>) | A, O | Abdelnour et al., 1993; Blevins et al., 2003; Gillaspay et al., 1995 |
| Alpha-toxin and gamma-toxin | A | Gemmell et al., 1997; Nilsson et al., 1999 |
| Collagen adhesin (<i>Cna</i>) | A, O | Elasri et al., 2002; Nilsson et al., 1998; Patti et al., 1994; Xu et al., 2004 |
| Clumping factor (<i>ClfA</i>) | A | Josefsson et al., 2001; Palmqvist et al., 2004, 2005 |
| Capsular polysaccharide | A | Nilsson et al., 1997 |
| DltA (D-alanine modification of teichoic acid) | A | Collins et al., 2002 |
| Fibronectin-binding proteins | O | Johansson et al., 2001 |
| MgrA (a global regulator) | A | Jonsson et al., 2008 |
| MprF (L-lysine modification of membrane lipids) | A | Peschel et al., 2001 |
| Peptidoglycan | A | Liu et al., 2001 |
| Pls (plasmin-sensitive protein) | A | Josefsson et al., 2005 |
| Protein A | A | Gemmell et al., 1997; Palmqvist et al., 2002 |
| Ribonucleotide reductase class III | A | Kirdis et al., 2007 |
| Sigma factor B (σ^B) and sigma factor S (σ^S) | | Jonsson et al., 2004; Shaw et al., 2008 |
| Sortase SrtA (responsible for anchoring many adhesins to the bacterial cell wall) | A | Jonsson et al., 2002 |
| Small colony variant phenotype | A | Jonsson et al., 2003 |
| Staphylococcal accessory regulator | A, O | Blevins et al., 2003 |
| Staphylococcal DNA | A | Deng et al., 1999 |
| Staphylococcal superantigens | A | Abdelnour et al., 1994; Bremell and Tarkowski, 1995 |
| Two putative lytic transglycosylases, <i>IsaA</i> and <i>SceD</i> | A | Stapleton et al., 2007 |

A, arthritis; O, osteomyelitis.

indicating a role for FnBPs in the systemic inflammatory response (Palmqvist et al., 2005).

One area of research that has received surprisingly little attention is that of the direct action of virulence factors on bone and bone cells. Work in our own laboratory has shown that *S. aureus* and *S. epidermidis* produce surface-associated proteins that can stimulate bone breakdown in an in vitro assay (Meghji et al., 1997; Nair et al., 1995). These surface-associated proteins and capsular material appear to promote the formation and activation of the bone-resorbing osteoclast (Lau et al., 2006; Meghji et al., 1998). Interestingly, a proportion of the population have antibodies that can block the action of the *S. aureus* proteins and prevent bone breakdown (Nair et al., 1997). The identity of the protein(s) in these mixtures which cause bone destruction has not been elucidated.

Small colony variants

Variant forms of *S. aureus*, known as small colony variants (SCVs), are associated with infections of bone and joint that may be particularly persistent, recurrent and refractory to antibiotic treatment (von Eiff et al., 2006). These bacteria are mutant forms of *Staphylococcus* that may have an adaptive advantage enabling persistent bone colonisation. SCV forms of coagulase-negative staphylococci, including *S. epidermidis*, *S. lugdunensis* and *S. capitis* have also been isolated from a range of infections (Adler et al., 2003; Seifert et al., 2005; von Eiff et al., 1999, 2006). The SCV phenotype is characterised by slow growth, with colonies around 10-fold smaller than wild-type forms, often with decreased pigmentation, increased aminoglycoside resistance and some reports of reduced haemolytic activity (Sendi and Proctor, 2009). The nature of these phenotypes can cause difficulty in detection and identification of the bacteria, and may contribute to an underestimation of the clinical prevalence of SCVs (von Eiff, 2008). These phenotypes usually result from auxotrophy for hemin, menadione or thymidine and can be reversed by supplementation with these molecules (Proctor et al., 1995, 2006). Mutations in the *hemB* and *menD* genes produce hemin and menadione auxotrophic strains with typical SCV phenotypes,

and give rise to disruption of electron transport which is the basis of the growth deficiency, increased aminoglycoside resistance and other phenotypes (Bates et al., 2003; Proctor et al., 2006; von Eiff et al., 1997b). SCVs can be selected for with gentamicin in vitro, and there is evidence that antibiotic therapy, in particular use of gentamicin beads, which are used in addition to debridement and systemic antibiotic therapy for osteomyelitis may select for SCVs in clinical situations (Musher et al., 1977; von Eiff et al., 1997a). In a cohort of fourteen patients with confirmed *S. aureus* osteomyelitis, SCVs were isolated only from those four that had received gentamicin bead therapy, with the remaining ten patients harbouring normal *S. aureus* strains. Of the four SCVs, three were auxotrophic for hemin, and one for menadione. Only the patients harbouring SCVs had recurrent infections, although only patients whose gentamicin bead therapy had failed were included in the study (von Eiff et al., 1997a). SCVs have also been isolated from cases of infection of hip prostheses, and intracellular bacteria within host fibroblasts were identified in one of the five instances (Sendi et al., 2006).

Clinically isolated SCVs with hemin auxotrophy, and defined *hemB* mutants, show enhanced intracellular persistence in a range of human cell types (Moisan et al., 2006; Vaudaux et al., 2002; von Eiff et al., 1997b, 2001). The basis of this persistence is not established but may involve a number of possible mechanisms. *S. aureus hemB* mutants exhibit enhanced binding to fibrinogen and fibronectin, and transcribe and display more *ClfA* and FnBP on their surface, which may increase attachment and uptake by host cells (Vaudaux et al., 2002). Transcriptional profiling of clinical and defined mutant SCVs reveals increased transcription of genes regulated by σ^B , including adhesin genes, and down-regulation of exoprotein and toxin genes (Moisan et al., 2006). The effect of increased σ^B activity on MSCRAMM expression has been shown to correlate well with osteoblast invasion, adding weight to the argument that σ^B -mediated up-regulation of adhesins increases host cell invasion, at least in vitro, and that increased invasion by SCVs may be partially dependent on this mechanism (Moisan et al., 2006; Nair et al., 2003). It has been argued that reduced production of toxins, particularly haemolysins, by SCVs also contributes to intracellular persistence by reducing the cytotoxic effect on host cells (Moisan et al., 2006; Sendi and Proctor, 2009; von Eiff et al., 1997b).

In a murine septic arthritis model, a defined stable *hemB* mutant, exhibiting the SCV phenotype, elicited more frequent and severe arthritis than the parental strain despite a reduced bacterial load in the kidney and joints. It has been argued that SCVs are therefore more virulent on a 'per organism' basis and that enhanced protease production by *hemB* mutants may partially explain this (Jonsson et al., 2003). It may be that in clinical infections relatively small numbers of SCVs with enhanced virulence survive within tissues, possibly intracellularly, for extended periods and cause persistent infections. Clinically isolated SCVs are able to revert to the parent phenotype, although to what extent this may play a role in infections, and whether *S. aureus* may 'switch' between states in different in vivo situations is currently unclear.

Conclusions

Staphylococcus species are a major cause of debilitating bone disease globally, a situation that shows no sign of abating. The increasing antibiotic resistance of staphylococci, combined with the greater opportunity for infection afforded by escalating numbers of orthopaedic surgical procedures will only serve to exacerbate the problem. Furthermore, evidence is now emerging that staphylococci are facultative intracellular pathogens, and are able to exploit this protected niche during bone infection to enhance persistence. Spontaneously arising mutant forms, such as SCVs, may be particularly adapted to this lifestyle, complicating the treatment of these infections further. Although host factors involved in the inflammatory destruction of bone are increasingly well understood, the staphylococcal virulence determinants directly involved in skeletal colonisation and destruction are less well characterised. Continued focus on elucidating the complex interactions between host and pathogen in these invasive skeletal infections is required to develop more effective treatment regimes. Enhanced understanding of these interactions will not only inform improved clinical management of bone disease, but may well open up new avenues for therapeutic development.

Acknowledgement

We are grateful to the Arthritis Research Campaign for project grant funding (grant number 18294).

References

- Abdelnour, A., Arvidson, S., Bremell, T., Ryden, C., Tarkowski, A., 1993. The accessory gene regulator (*agr*) controls *Staphylococcus aureus* virulence in a murine arthritis model. *Infect. Immun.* 61, 3879–3885.
- Abdelnour, A., Bremell, T., Tarkowski, A., 1994. Toxic shock syndrome toxin 1 contributes to the arthritogenicity of *Staphylococcus aureus*. *J. Infect. Dis.* 170, 94–99.
- Adler, H., Widmer, A., Frei, R., 2003. Emergence of a teicoplanin-resistant small colony variant of *Staphylococcus epidermidis* during vancomycin therapy. *Eur. J. Clin. Microbiol. Infect. Dis.* 22, 746–748.
- Agerer, F., Lux, S., Michel, A., Rohde, M., Ohlsen, K., Hauck, C.R., 2005. Cellular invasion by *Staphylococcus aureus* reveals a functional link between focal adhesion kinase and cortactin in integrin-mediated internalisation. *J. Cell Sci.* 118, 2189–2200.
- Aggarwal, B.B., 2003. Signalling pathways of the TNF superfamily: a double-edged sword. *Nat. Rev. Immunol.* 3, 745–756.
- Ahmed, S., Meghji, S., Williams, R.J., Henderson, B., Brock, J.H., Nair, S.P., 2001. *Staphylococcus aureus* fibronectin binding proteins are essential for internalization by osteoblasts but do not account for differences in intracellular levels of bacteria. *Infect. Immun.* 69, 2872–2877.
- Al Arafaj, A.S., 2008. A prospective study of the incidence and characteristics of septic arthritis in a teaching hospital in Riyadh, Saudi Arabia. *Clin. Rheumatol.* 27, 1403–1410.
- Alexander, E.H., Rivera, F.A., Marriott, I., Anguita, J., Bost, K.L., Hudson, M.C., 2003. *Staphylococcus aureus*-induced tumor necrosis factor-related apoptosis-inducing ligand expression mediates apoptosis and caspase-8 activation in infected osteoblasts. *BMC Microbiol.* 3, 5.
- Angel, N.Z., Walsh, N., Forwood, M.R., Ostrowski, M.C., Cassady, A.I., Hume, D.A., 2000. Transgenic mice overexpressing tartrate-resistant acid phosphatase exhibit an increased rate of bone turnover. *J. Bone Miner. Res.* 15, 103–110.
- Arciola, C.R., Campoccia, D., Gamberini, S., Baldassarri, L., Montanaro, L., 2005. Prevalence of *cna*, *fnbA* and *fnbB* adhesin genes among *Staphylococcus aureus* isolates from orthopedic infections associated to different types of implant. *FEMS Microbiol. Lett.* 246, 81–86.
- Arend, W.P., Palmer, G., Gabay, C., 2008. IL-1, IL-18, and IL-33 families of cytokines. *Immunol. Rev.* 223, 20–38.
- Arnold, S.R., Elias, D., Buckingham, S.C., Thomas, E.D., Novias, E., Arkader, A., Howard, C., 2006. Changing patterns of acute hematogenous osteomyelitis and septic arthritis: emergence of community-associated methicillin-resistant *Staphylococcus aureus*. *J. Pediatr. Orthop.* 26, 703–708.
- Assuma, R., Oates, T., Cochran, D., Amar, S., Graves, D.T., 1998. IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. *J. Immunol.* 160, 403–409.
- Azuma, Y., Kaji, K., Katogi, R., Takeshita, S., Kudo, A., 2000. Tumor necrosis factor- α induces differentiation of and bone resorption by osteoclasts. *J. Biol. Chem.* 275, 4858–4864.
- Bates, D.M., von, E.C., McNamara, P.J., Peters, G., Yeaman, M.R., Bayer, A.S., Proctor, R.A., 2003. *Staphylococcus aureus menD* and *hemB* mutants are as infective as the parent strains, but the menadione biosynthetic mutant persists within the kidney. *J. Infect. Dis.* 187, 1654–1661.
- Bennet, G.C., Bennet, S.J., 2006. Infection of bone and joint. *Surgery (Oxford)* 24, 211–214.
- Berendt, T., Byren, I., 2004. Bone and joint infection. *Clin. Med.* 4, 510–518.
- Blair, H.C., 1998. How the osteoclast degrades bone. *Bioessays* 20, 837–846.
- Blair, H.C., Teitelbaum, S.L., Ghiselli, R., Gluck, S., 1989. Osteoclastic bone resorption by a polarized vacuolar proton pump. *Science* 245, 855–857.
- Blevins, J.S., Elashi, M.O., Allmendinger, S.D., Beenken, K.E., Skinner, R.A., Thomas, J.R., Smeltzer, M.S., 2003. Role of *sarA* in the pathogenesis of *Staphylococcus aureus* musculoskeletal infection. *Infect. Immun.* 71, 516–523.
- Blyth, M.J., Kincaid, R., Craigen, M.A., Bennet, G.C., 2001. The changing epidemiology of acute and subacute haematogenous osteomyelitis in children. *J. Bone Joint Surg. Br.* 83, 99–102.
- Bocchini, C.E., Hulten, K.G., Mason Jr., E.O., Gonzalez, B.E., Hammerman, W.A., Kaplan, S.L., 2006. Pantone-Valentine leukocidin genes are associated with enhanced inflammatory response and local disease in acute hematogenous *Staphylococcus aureus* osteomyelitis in children. *Pediatrics* 117, 433–440.
- Bossard, M.J., Tomaszek, T.A., Thompson, S.K., Amegadzie, B.Y., Hanning, C.R., Jones, C., Kurdyła, J.T., McNulty, D.E., Drake, F.H., Gowen, M., Levy, M.A., 1996. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. *J. Biol. Chem.* 271, 12517–12524.
- Bosse, M.J., Gruber, H.E., Ramp, W.K., 2005. Internalization of bacteria by osteoblasts in a patient with recurrent, long-term osteomyelitis. A case report. *J. Bone Joint Surg. Am.* 87, 1343–1347.
- Bost, K.L., Ramp, W.K., Nicholson, N.C., Bento, J.L., Marriott, I., Hudson, M.C., 1999. *Staphylococcus aureus* infection of mouse or human osteoblasts induces high levels of interleukin-6 and interleukin-12 production. *J. Infect. Dis.* 180, 1912–1920.
- Boulter, E., Van Obberghen-Schilling, E., 2006. Integrin-linked kinase and its partners: a modular platform regulating cell-matrix adhesion dynamics and cytoskeletal organization. *Eur. J. Cell Biol.* 85, 255–263.
- Boyce, B.F., Xing, L., 2008. Functions of RANKL/RANK/OPG in bone modeling and remodeling. *Arch. Biochem. Biophys.* 473, 139–146.
- Boyden, E.D., Dietrich, W.F., 2006. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. *Nat. Genet.* 38, 240–244.
- Bradley, J.R., 2008. TNF-mediated inflammatory disease. *J. Pathol.* 214, 149–160.
- Bremell, T., Tarkowski, A., 1995. Preferential induction of septic arthritis and mortality by superantigen-producing staphylococci. *Infect. Immun.* 63, 4185–4187.
- Bremell, T., Lange, S., Yacoub, A., Ryden, C., Tarkowski, A., 1991. Experimental *Staphylococcus aureus* arthritis in mice. *Infect. Immun.* 59, 2615–2623.
- Bremell, T., Abdelnour, A., Tarkowski, A., 1992. Histopathological and serological progression of experimental *Staphylococcus aureus* arthritis. *Infect. Immun.* 60, 2976–2985.
- Bu, R., Borysenko, C.W., Li, Y., Cao, L., Sabokbar, A., Blair, H.C., 2003. Expression and function of TNF-family proteins and receptors in human osteoblasts. *Bone* 33, 760–770.
- Canalis, E., 1987. Effects of tumor necrosis factor on bone formation in vitro. *Endocrinology* 121, 1596–1604.
- Cassat, J.E., Dunman, P.M., McAleese, F., Murphy, E., Projan, S.J., Smeltzer, M.S., 2005. Comparative genomics of *Staphylococcus aureus* musculoskeletal isolates. *J. Bacteriol.* 187, 576–592.
- Centrella, M., McCarthy, T.L., Canalis, E., 1988. Tumor necrosis factor- α inhibits collagen synthesis and alkaline phosphatase activity independently of its effect on deoxyribonucleic acid synthesis in osteoblast-enriched bone cell cultures. *Endocrinology* 123, 1442–1448.
- Chiang, C.Y., Kyritsis, G., Graves, D.T., Amar, S., 1999. Interleukin-1 and tumor necrosis factor activities partially account for calvarial bone resorption induced by local injection of lipopolysaccharide. *Infect. Immun.* 67, 4231–4236.
- Ciampolini, J., Harding, K.G., 2000. Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often? *Postgrad. Med. J.* 76, 479–483.
- Collins, L.V., Kristian, S.A., Weidenmaier, C., Faigle, M., van Kessel, K.P., van Strijp, J.A., Gotz, F., Neumeister, B., Peschel, A., 2002. *Staphylococcus aureus* strains lacking D-alanine modifications of teichoic acids are highly susceptible to

- human neutrophil killing and are virulence attenuated in mice. *J. Infect. Dis.* 186, 214–219.
- Colucci, S., Brunetti, G., Cantatore, F.P., Oranger, A., Mori, G., Pignataro, P., Tamma, R., Grassi, F.R., Zallone, A., Grano, M., 2007. The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis. *Apoptosis* 12, 1623–1632.
- Creagh, E.M., O'Neill, L.A., 2006. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. *Trends Immunol.* 27, 352–357.
- Darouiche, R.O., Landon, G.C., Patti, J.M., Nguyen, L.L., Fernau, R.C., McDevitt, D., Greene, C., Foster, T., Klima, M., 1997. Role of *Staphylococcus aureus* surface adhesins in orthopaedic device infections: are results model-dependent? *J. Med. Microbiol.* 46, 75–79.
- Deng, G.M., Nilsson, I.M., Verdrengh, M., Collins, L.V., Tarkowski, A., 1999. Intrarticularly localized bacterial DNA containing CpG motifs induces arthritis. *Nat. Med.* 5, 702–705.
- Dinarello, C.A., 2009. Immunological and inflammatory functions of the interleukin-1 family. *Annu. Rev. Immunol.* 27, 519–550.
- Drake, F.H., Dodds, R.A., James, I.E., Connor, J.R., Debouck, C., Richardson, S., Lee-Rykaczewski, E., Coleman, L., Rieman, D., Barthlow, R., Hastings, G., Gowen, M., 1996. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. *J. Biol. Chem.* 271, 12511–12516.
- Dubost, J.J., Soubrier, M., De, C.C., Ristori, J.M., Bussiere, J.L., Sauvezie, B., 2002. No changes in the distribution of organisms responsible for septic arthritis over a 20 year period. *Ann. Rheum. Dis.* 61, 267–269.
- Dziewanowska, K., Patti, J.M., Deobald, C.F., Bayles, K.W., Trumble, W.R., Bohach, G.A., 1999. Fibronectin binding protein and host cell tyrosine kinase are required for internalization of *Staphylococcus aureus* by epithelial cells. *Infect. Immun.* 67, 4673–4678.
- Ek-Rylander, B., Bill, P., Norgard, M., Nilsson, S., Andersson, G., 1991. Cloning, sequence, and developmental expression of a type 5, tartrate-resistant, acid phosphatase of rat bone. *J. Biol. Chem.* 266, 24684–24689.
- Elasri, M.O., Thomas, J.R., Skinner, R.A., Blevins, J.S., Beenken, K.E., Nelson, C.L., Smeltzer, M.S., 2002. *Staphylococcus aureus* collagen adhesin contributes to the pathogenesis of osteomyelitis. *Bone* 30, 275–280.
- Ellington, J.K., Reilly, S.S., Ramp, W.K., Smeltzer, M.S., Kellam, J.F., Hudson, M.C., 1999. Mechanisms of *Staphylococcus aureus* invasion of cultured osteoblasts. *Microb. Pathog.* 26, 317–323.
- Evans, C.A., Jellis, J., Hughes, S.P., Remick, D.G., Friedland, J.S., 1998. Tumor necrosis factor- α , interleukin-6, and interleukin-8 secretion and the acute-phase response in patients with bacterial and tuberculous osteomyelitis. *J. Infect. Dis.* 177, 1582–1587.
- Everts, V., Korper, W., Hoeben, K.A., Jansen, I.D., Bromme, D., Cleutjens, K.B., Heeneman, S., Peters, C., Reinheckel, T., Saftig, P., Beertsen, W., 2006. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. *J. Bone Miner. Res.* 21, 1399–1408.
- Faustin, B., Lartigue, L., Bruey, J.M., Luciano, F., Sergienko, E., Bailly-Maitre, B., Volkman, N., Hanein, D., Rouiller, I., Reed, J.C., 2007. Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. *Mol. Cell* 25, 713–724.
- Feil, E.J., Cooper, J.E., Grundmann, H., Robinson, D.A., Enright, M.C., Berendt, T., Peacock, S.J., Smith, J.M., Murphy, M., Spratt, B.G., Moore, C.E., Day, N.P., 2003. How clonal is *Staphylococcus aureus*? *J. Bacteriol.* 185, 3307–3316.
- Fowler, T., Wann, E.R., Joh, D., Johansson, S., Foster, T.J., Hook, M., 2000. Cellular invasion by *Staphylococcus aureus* involves a fibronectin bridge between the bacterial fibronectin-binding MSCRAMMs and host cell beta1 integrins. *Eur. J. Cell Biol.* 79, 672–679.
- Franchi, L., Amer, A., Body-Malapel, M., Kanneganti, T.D., Ozoren, N., Jagirdar, R., Inohara, N., Vandenabeele, P., Bertin, J., Coyle, A., Grant, E.P., Nunez, G., 2006. Cytosolic flagellin requires I κ B α for activation of caspase-1 and interleukin 1[β] in *Salmonella*-infected macrophages. *Nat. Immunol.* 7, 576–582.
- Gallie, W., 1951. First recurrence of osteomyelitis eighty years after infection. *J. Bone Joint Surg. Br.* 33-B, 110–111.
- Garcia-Alvarez, F., Navarro-Zorraquino, M., Castro, A., Grasa, J.M., Pastor, C., Monzon, M., Martinez, A., Garcia-Alvarez, I., Castillo, J., Lozano, R., 2009. Effect of age on cytokine response in an experimental model of osteomyelitis. *Biogerontology* 10, 649–658.
- Garzoni, C., Kelley, W.L., 2009. *Staphylococcus aureus*: new evidence for intracellular persistence. *Trends Microbiol.* 17, 59–65.
- Gemmell, C.G., Goutcher, S.C., Reid, R., Sturrock, R.D., 1997. Role of certain virulence factors in a murine model of *Staphylococcus aureus* arthritis. *J. Med. Microbiol.* 46, 208–213.
- Gillaspay, A.F., Hickmon, S.G., Skinner, R.A., Thomas, J.R., Nelson, C.L., Smeltzer, M.S., 1995. Role of the accessory gene regulator (*agr*) in pathogenesis of staphylococcal osteomyelitis. *Infect. Immun.* 63, 3373–3380.
- Gillespie, W.J., 1990. Epidemiology in bone and joint infection. *Infect. Dis. Clin. North Am.* 4, 361–376.
- Goldenberg, D.L., 1998. Septic arthritis. *Lancet* 351, 197–202.
- Gomez, M.I., Lee, A., Reddy, B., Muir, A., Soong, G., Pitt, A., Cheung, A., Prince, A., 2004. *Staphylococcus aureus* protein A induces airway epithelial inflammatory responses by activating TNFR1. *Nat. Med.* 10, 842–848.
- Grammatico, L., Baron, S., Rusch, E., Lepage, B., Surer, N., Desenclos, J.C., Besnier, J.M., 2008. Epidemiology of vertebral osteomyelitis (VO) in France: analysis of hospital-discharge data 2002–2008. *Epidemiol. Infect.* 136, 653–660.
- Greer, R.B., Rosenberg, A.E., 1993. Case 6 – 1993 – A 69-year-old woman with a sclerotic lesion of the femur and pulmonary nodules. *N. Engl. J. Med.* 328, 422–428.
- Greig, J.M., Wood, M.J., 2003. *Staphylococcus lugdunensis* vertebral osteomyelitis. *Clin. Microbiol. Infect.* 9, 1139–1141.
- Guschin, D., Rogers, N., Briscoe, J., Witthuhn, B., Watling, D., Horn, F., Pellegrini, S., Yasukawa, K., Heinrich, P., Stark, G.R., 1995. A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. *EMBO J.* 14, 1421–1429.
- Hattersley, G., Dorey, E., Horton, M.A., Chambers, T.J., 1988. Human macrophage colony-stimulating factor inhibits bone resorption by osteoclasts disaggregated from rat bone. *J. Cell. Physiol.* 137, 199–203.
- Hauck, C.R., Ohlsen, K., 2006. Sticky connections: extracellular matrix protein recognition and integrin-mediated cellular invasion by *Staphylococcus aureus*. *Curr. Opin. Microbiol.* 9, 5–11.
- Hayman, A.R., Cox, T.M., 1994. Purple acid phosphatase of the human macrophage and osteoclast. Characterization, molecular properties, and crystallization of the recombinant di-iron-oxo protein secreted by baculovirus-infected insect cells. *J. Biol. Chem.* 269, 1294–1300.
- Hayman, A.R., Jones, S.J., Boyde, A., Foster, D., Colledge, W.H., Carlton, M.B., Evans, M.J., Cox, T.M., 1996. Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis. *Development* 122, 3151–3162.
- Heinrich, P.C., Bode, J., Decker, M., Graeve, L., Martens, A., Muller-Newen, G., Pflanz, S., Schaper, F., Schmitz, J., 2001. Termination and modulation of IL-6-type cytokine signaling. *Adv. Exp. Med. Biol.* 495, 153–160.
- Heinrich, P.C., Behrmann, I., Haan, S., Hermanns, H.M., Muller-Newen, G., Schaper, F., 2003. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. *Biochem. J.* 374, 1–20.
- Henderson, B., Nair, S.P., 2003. Hard labour: bacterial infection of the skeleton. *Trends Microbiol.* 11, 570–577.
- Henriksen, K., Neutzsky-Wulff, A.V., Bonewald, L.F., Karsdal, M.A., 2009. Local communication on and within bone controls bone remodeling. *Bone* 44, 1026–1033.
- Hikita, A., Yana, I., Wakeyama, H., Nakamura, M., Kadono, Y., Oshima, Y., Nakamura, K., Seiki, M., Tanaka, S., 2006. Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF- κ B ligand. *J. Biol. Chem.* 281, 36846–36855.
- Hudson, M.C., Ramp, W.K., Nicholson, N.C., Williams, A.S., Nousiainen, M.T., 1995. Internalization of *Staphylococcus aureus* by cultured osteoblasts. *Microb. Pathog.* 19, 409–419.
- Ishimi, Y., Miyaura, C., Jin, C.H., Akatsu, T., Abe, E., Nakamura, Y., Yamaguchi, A., Yoshiki, S., Matsuda, T., Hirano, T., 1990. IL-6 is produced by osteoblasts and induces bone resorption. *J. Immunol.* 145, 3297–3303.
- Jevon, M., Guo, C., Ma, B., Mordan, N., Nair, S.P., Harris, M., Henderson, B., Bentley, G., Meghji, S., 1999. Mechanisms of internalization of *Staphylococcus aureus* by cultured human osteoblasts. *Infect. Immun.* 67, 2677–2681.
- Johansson, A., Flock, J.I., Svensson, O., 2001. Collagen and fibronectin binding in experimental staphylococcal osteomyelitis. *Clin. Orthop. Relat. Res.* 241–246.
- Jonsson, I.M., Mazmanian, S.K., Schneewind, O., Verdrengh, M., Bremell, T., Tarkowski, A., 2002. On the role of *Staphylococcus aureus* sortase and sortase-catalyzed surface protein anchoring in murine septic arthritis. *J. Infect. Dis.* 185, 1417–1424.
- Jonsson, I.M., vonEiff, C., Proctor, R.A., Peters, G., Ryden, C., Tarkowski, A., 2003. Virulence of a *hmbB* mutant displaying the phenotype of a *Staphylococcus aureus* small colony variant in a murine model of septic arthritis. *Microb. Pathog.* 34, 73–79.
- Jonsson, I.M., Arvidson, S., Foster, S., Tarkowski, A., 2004. Sigma factor B and RsbU are required for virulence in *Staphylococcus aureus*-induced arthritis and sepsis. *Infect. Immun.* 72, 6106–6111.
- Jonsson, I.M., Lindholm, C., Luong, T.T., Lee, C.Y., Tarkowski, A., 2008. *mgrA* regulates staphylococcal virulence important for induction and progression of septic arthritis and sepsis. *Microbes Infect.* 10, 1229–1235.
- Josefsson, E., Hartford, O., O'Brien, L., Patti, J.M., Foster, T., 2001. Protection against experimental *Staphylococcus aureus* arthritis by vaccination with clumping factor A, a novel virulence determinant. *J. Infect. Dis.* 184, 1572–1580.
- Josefsson, E., Juuti, K., Bokarewa, M., Kuusela, P., 2005. The surface protein Pls of methicillin-resistant *Staphylococcus aureus* is a virulence factor in septic arthritis. *Infect. Immun.* 73, 2812–2817.
- Kahlenberg, J.M., Lundberg, K.C., Kertesz, S.B., Qu, Y., Dubyak, G.R., 2005. Potentiation of caspase-1 activation by the P2 \times 7 receptor is dependent on TLR signals and requires NF- κ B-driven protein synthesis. *J. Immunol.* 175, 7611–7622.
- Kanazawa, K., Azuma, Y., Nakano, H., Kudo, A., 2003. TRAF5 functions in both RANKL- and TNF-induced osteoclastogenesis. *J. Bone Miner. Res.* 18, 443–450.
- Kanazawa, K., Kudo, A., 2005. TRAF2 is essential for TNF- α -induced osteoclastogenesis. *J. Bone Miner. Res.* 20, 840–847.
- Karwowska, A., Davies, H.D., Jadavji, T., 1998. Epidemiology and outcome of osteomyelitis in the era of sequential intravenous-oral therapy. *Pediatr. Infect. Dis. J.* 17, 1021–1026.
- Khalil, H., Williams, R.J., Stenbeck, G., Henderson, B., Meghji, S., Nair, S.P., 2007. Invasion of bone cells by *Staphylococcus epidermidis*. *Microbes Infect.* 9, 460–465.
- Kim, H.H., Lee, D.E., Shin, J.N., Lee, Y.S., Jeon, Y.M., Chung, C.H., Ni, J., Kwon, B.S., Lee, Z.H., 1999. Receptor activator of NF- κ B recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase. *FEBS Lett.* 443, 297–302.
- Kintarak, S., Whawell, S.A., Speight, P.M., Packer, S., Nair, S.P., 2004. Internalization of *Staphylococcus aureus* by human keratinocytes. *Infect. Immun.* 72, 5668–5675.

- Kirdis, E., Jonsson, I.M., Kubica, M., Potempa, J., Josefsson, E., Masalha, M., Foster, S.J., Tarkowski, A., 2007. Ribonucleotide reductase class III, an essential enzyme for the anaerobic growth of *Staphylococcus aureus*, is a virulence determinant in septic arthritis. *Microb. Pathog.* 43, 179–188.
- Klosterhalfen, B., Peters, K.M., Tons, C., Hauptmann, S., Klein, C.L., Kirkpatrick, C.J., 1996. Local and systemic inflammatory mediator release in patients with acute and chronic posttraumatic osteomyelitis. *J. Trauma* 40, 372–378.
- Konig, A., Muhlbauer, R.C., Fleisch, H., 1988. Tumor necrosis factor alpha and interleukin-1 stimulate bone resorption in vivo as measured by urinary [³H]tetracycline excretion from prelabeled mice. *J. Bone Miner. Res.* 3, 621–627.
- Kornak, U., Kasper, D., Bosl, M.R., Kaiser, E., Schweizer, M., Schulz, A., Friedrich, W., Dellling, G., Jentsch, T.J., 2001. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. *Cell* 104, 205–215.
- Korovessis, P., Fortis, A.P., Spastris, P., Droutsas, P., 1991. Acute osteomyelitis of the patella 50 years after a knee fusion for septic arthritis. A case report. *Clin. Orthop. Relat. Res.*, 205–207.
- Kotake, S., Sato, K., Kim, K.J., Takahashi, N., Udagawa, N., Nakamura, I., Yamaguchi, A., Kishimoto, T., Suda, T., Kashiwazaki, S., 1996. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. *J. Bone Miner. Res.* 11, 88–95.
- Kwan, T.S., Padrines, M., Theoleyre, S., Heymann, D., Fortun, Y., 2004. IL-6, RANKL, TNF- α /IL-1: interrelations in bone resorption pathophysiology. *Cytokine Growth Factor Rev.* 15, 49–60.
- Lacey, D.C., Simmons, P.J., Graves, S.E., Hamilton, J.A., 2008. Proinflammatory cytokines inhibit osteogenic differentiation from stem cells: implications for bone repair during inflammation. *Osteoarthritis Cartilage* 17, 735–742.
- Lang, S., Livesley, M.A., Lambert, P.A., Elliott, J., Elliott, T.S., 1999. The genomic diversity of coagulase-negative staphylococci associated with nosocomial infections. *J. Hosp. Infect.* 43, 187–193.
- Lau, Y.S., Wang, W., Sabokbar, A., Simpson, H., Nair, S., Henderson, B., Berendt, A., Athanasou, N.A., 2006. *Staphylococcus aureus* capsular material promotes osteoclast formation. *Injury* 37 (Suppl. 2), S41–S48.
- Lazzarini, L., Mader, J.T., Calhoun, J.H., 2004. Osteomyelitis in long bones. *J. Bone Joint Surg. Am.* 86-A, 2305–2318.
- Lee, K., Goodman, S.B., 2008. Current state and future of joint replacements in the hip and knee. *Expert Rev. Med. Devices* 5, 383–393.
- Levine, M., Siegel, L.B., 2003. A swollen joint: why all the fuss?. *Am. J. Ther.* 10, 219–224.
- Lew, D.P., Waldvogel, F.A., 1997. Osteomyelitis. *N. Engl. J. Med.* 336, 999–1007.
- Lew, D.P., Waldvogel, F.A., 2004. Osteomyelitis. *Lancet* 364, 369–379.
- Li, W., Liang, X., Kellendonk, C., Poli, V., Taub, R., 2002. STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. *J. Biol. Chem.* 277, 28411–28417.
- Li, Y.P., Stashenko, P., 1992. Proinflammatory cytokines tumor necrosis factor- α and IL-6, but not IL-1, down-regulate the osteocalcin gene promoter. *J. Immunol.* 148, 788–794.
- Lindsay, J.A., Moore, C.E., Day, N.P., Peacock, S.J., Witney, A.A., Stabler, R.A., Husain, S.E., Butcher, P.D., Hinds, J., 2006. Microarrays reveal that each of the ten dominant lineages of *Staphylococcus aureus* has a unique combination of surface-associated and regulatory genes. *J. Bacteriol.* 188, 669–676.
- Liu, Z.Q., Deng, G.M., Foster, S., Tarkowski, A., 2001. Staphylococcal peptidoglycans induce arthritis. *Arthritis Res.* 3, 375–380.
- Ljusberg, J., Wang, Y., Lang, P., Norgard, M., Dodds, R., Hultenby, K., Ek-Rylander, B., Andersson, G., 2005. Proteolytic excision of a repressive loop domain in tartrate-resistant acid phosphatase by cathepsin K in osteoclasts. *J. Biol. Chem.* 280, 28370–28381.
- Lomaga, M.A., Yeh, W.C., Sarosi, I., Duncan, G.S., Furlonger, C., Ho, A., Morony, S., Capparelli, C., Van, G., Kaufman, S., van der, H.A., Itie, A., Wakeham, A., Khoo, W., Sasaki, T., Cao, Z., Penninger, J.M., Paige, C.J., Lacey, D.L., Dunstan, C.R., Boyle, W.J., Goeddel, D.V., Mak, T.W., 1999. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. *Genes Dev.* 13, 1015–1024.
- Lynch, C.C., Hikosaka, A., Acuff, H.B., Martin, M.D., Kawai, N., Singh, R.K., Vargogogola, T.C., Begtrup, J.L., Peterson, T.E., Fingleton, B., Shirai, T., Matrisian, L.M., Futakuchi, M., 2005. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. *Cancer Cell* 7, 485–496.
- Mackie, E.J., 2003. Osteoblasts: novel roles in orchestration of skeletal architecture. *Int. J. Biochem. Cell Biol.* 35, 1301–1305.
- Mahalingam, D., Szegezdi, E., Keane, M., Jong, S., Samali, A., 2009. TRAIL receptor signalling and modulation: Are we on the right TRAIL?. *Cancer Treat. Rev.* 35, 280–288.
- Mariathasan, S., Weiss, D.S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., Lee, W.P., Weinrauch, Y., Monack, D.M., Dixit, V.M., 2006. Cryopyrin activates the inflammasome in response to toxins and ATP. *Nature* 440, 228–232.
- Marriott, I., Hughes Jr., F.M., Bost, K.L., 2002. Bacterial infection of osteoblasts induces interleukin-1 β and interleukin-18 transcription but not protein synthesis. *J. Interferon Cytokine Res.* 22, 1049–1055.
- Matsuo, K., Irie, N., 2008. Osteoclast-osteoblast communication. *Arch. Biochem. Biophys.* 473, 201–209.
- McCall, S.H., Sahraei, M., Young, A.B., Worley, C.S., Duncan, J.A., Ting, J.P., Marriott, I., 2008. Osteoblasts express NLRP3, a nucleotide-binding domain and leucine-rich repeat region containing receptor implicated in bacterially induced cell death. *J. Bone Miner. Res.* 23, 30–40.
- Meghji, S., Crean, S.J., Nair, S., Wilson, M., Poole, S., Harris, M., Henderson, B., 1997. *Staphylococcus epidermidis* produces a cell-associated proteinaceous fraction which causes bone resorption by a prostanoind-independent mechanism: relevance to the treatment of infected orthopaedic implants. *Br. J. Rheumatol.* 36, 957–963.
- Meghji, S., Crean, S.J., Hill, P.A., Sheikh, M., Nair, S.P., Heron, K., Henderson, B., Mawer, E.B., Harris, M., 1998. Surface-associated protein from *Staphylococcus aureus* stimulates osteoclastogenesis: possible role in *S. aureus*-induced bone pathology. *Br. J. Rheumatol.* 37, 1095–1101.
- Miao, E.A., Puche-Aranda, C.M., Dors, M., Clark, A.E., Bader, M.W., Miller, S.I., Aderem, A., 2006. Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1[β] via Ipaf. *Nat. Immunol.* 7, 569–575.
- Mitchell, G., Lamontagne, C.A., Brouillette, E., Grondin, G., Talbot, B.G., Grandbois, M., Malouin, F., 2008. *Staphylococcus aureus* SigB activity promotes a strong fibronectin-bacterium interaction which may sustain host tissue colonization by small-colony variants isolated from cystic fibrosis patients. *Mol. Microbiol.* 70, 1540–1555.
- Moisan, H., Brouillette, E., Jacob, C.L., Langlois-Begin, P., Michaud, S., Malouin, F., 2006. Transcription of virulence factors in *Staphylococcus aureus* small-colony variants isolated from cystic fibrosis patients is influenced by SigB. *J. Bacteriol.* 188, 64–76.
- Mundy, G.R., 1991. Inflammatory mediators and the destruction of bone. *J. Periodontol. Res.* 26, 213–217.
- Murdoch, D.R., Everts, R.J., Chambers, S.T., Cowan, I.A., 1996. Vertebral osteomyelitis due to *Staphylococcus lugdunensis*. *J. Clin. Microbiol.* 34, 993–994.
- Musher, D.M., Baughn, R.E., Templeton, G.B., Minuth, J.N., 1977. Emergence of variant forms of *Staphylococcus aureus* after exposure to gentamicin and infectivity of the variants in experimental animals. *J. Infect. Dis.* 136, 360–369.
- Nade, S., 2003. Septic arthritis. *Best. Pract. Res. Clin. Rheumatol.* 17, 183–200.
- Nair, S., Song, Y., Meghji, S., Reddi, K., Harris, M., Ross, A., Poole, S., Wilson, M., Henderson, B., 1995. Surface-associated proteins from *Staphylococcus aureus* demonstrate potent bone resorbing activity. *J. Bone Miner. Res.* 10, 726–734.
- Nair, S.P., Meghji, S., Wilson, M., Nugent, I., Ross, A., Ismael, A., Bhudia, N.K., Harris, M., Henderson, B., 1997. Clinical isolates of *Staphylococcus aureus* have osteolytic surface proteins and a proportion of the population have antibodies that block this activity: is this of prognostic significance?. *Br. J. Rheumatol.* 36, 328–332.
- Nair, S.P., Bischoff, M., Senn, M.M., Berger-Bachi, B., 2003. The sigma B regulon influences internalization of *Staphylococcus aureus* by osteoblasts. *Infect. Immun.* 71, 4167–4170.
- Nanes, M.S., 2003. Tumor necrosis factor- α : molecular and cellular mechanisms in skeletal pathology. *Gene* 321, 1–15.
- Nanes, M.S., McKay, W.M., Marx, S.J., 1989. Inhibitory effects of tumor necrosis factor- α and interferon- γ on deoxyribonucleic acid and collagen synthesis by rat osteosarcoma cells (ROS 17/2.8). *Endocrinology* 124, 339–345.
- Nanes, M.S., Rubin, J., Titus, L., Hendy, G.N., Catherwood, B., 1991. Tumor necrosis factor- α inhibits 1,25-dihydroxyvitamin D₃-stimulated bone Gla protein synthesis in rat osteosarcoma cells (ROS 17/2.8) by a pretranslational mechanism. *Endocrinology* 128, 2577–2582.
- Naugler, W.E., Karin, M., 2008. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. *Trends Mol. Med.* 14, 109–119.
- Nesbitt, S.A., Horton, M.A., 1997. Trafficking of matrix collagens through bone-resorbing osteoclasts. *Science* 276, 266–269.
- Nilsson, I.M., Lee, J.C., Bremell, T., Ryden, C., Tarkowski, A., 1997. The role of staphylococcal polysaccharide microcapsule expression in septicemia and septic arthritis. *Infect. Immun.* 65, 4216–4221.
- Nilsson, I.M., Patti, J.M., Bremell, T., Hook, M., Tarkowski, A., 1998. Vaccination with a recombinant fragment of collagen adhesin provides protection against *Staphylococcus aureus*-mediated septic death. *J. Clin. Invest.* 101, 2640–2649.
- Nilsson, I.M., Hartford, O., Foster, T., Tarkowski, A., 1999. Alpha-toxin and gamma-toxin jointly promote *Staphylococcus aureus* virulence in murine septic arthritis. *Infect. Immun.* 67, 1045–1049.
- Osiri, M., Ruxrungtham, K., Nookhai, S., Ohmoto, Y., Deesomchok, U., 1998. IL-1 β , IL-6 and TNF- α in synovial fluid of patients with non-gonococcal septic arthritis. *Asian Pac. J. Allergy Immunol.* 16, 155–160.
- Palmqvist, N., Foster, T., Tarkowski, A., Josefsson, E., 2002. Protein A is a virulence factor in *Staphylococcus aureus* arthritis and septic death. *Microb. Pathog.* 33, 239–249.
- Palmqvist, N., Patti, J.M., Tarkowski, A., Josefsson, E., 2004. Expression of staphylococcal clumping factor A impedes macrophage phagocytosis. *Microbes Infect.* 6, 188–195.
- Palmqvist, N., Foster, T., Fitzgerald, J.R., Josefsson, E., Tarkowski, A., 2005. Fibronectin-binding proteins and fibrinogen-binding clumping factors play distinct roles in staphylococcal arthritis and systemic inflammation. *J. Infect. Dis.* 191, 791–798.
- Patti, J.M., Bremell, T., Krajewska-Pietrasik, D., Abdelnour, A., Tarkowski, A., Ryden, C., Hook, M., 1994. The *Staphylococcus aureus* collagen adhesin is a virulence determinant in experimental septic arthritis. *Infect. Immun.* 62, 152–161.
- Peacock, S.J., Day, N.P., Thomas, M.G., Berendt, A.R., Foster, T.J., 2000. Clinical isolates of *Staphylococcus aureus* exhibit diversity in *fmb* genes and adhesion to human fibronectin. *J. Infect.* 41, 23–31.
- Peacock, S.J., Moore, C.E., Justice, A., Kantzanou, M., Story, L., Mackie, K., O'Neill, G., Day, N.P., 2002. Virulent combinations of adhesin and toxin genes in natural populations of *Staphylococcus aureus*. *Infect. Immun.* 70, 4987–4996.
- Peschel, A., Jack, R.W., Otto, M., Collins, L.V., Staubitz, P., Nicholson, G., Kalbacher, H., Nieuwenhuizen, W.F., Jung, G., Tarkowski, A., van Kessel, K.P., van Strijp, J.A., 2001. *Staphylococcus aureus* resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with L-lysine. *J. Exp. Med.* 193, 1067–1076.

- Pfeilschifter, J., Chenu, C., Bird, A., Mundy, G.R., Roodman, G.D., 1989. Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclast-like cells in vitro. *J. Bone Miner. Res.* 4, 113–118.
- Pivrotto, L.A., Cissel, D.S., Keeting, P.E., 1995. Sex hormones mediate interleukin-1 beta production by human osteoblastic HOBIT cells. *Mol. Cell. Endocrinol.* 111, 67–74.
- Proctor, R.A., van, L.P., Kristjansson, M., Maslow, J.N., Arbeit, R.D., 1995. Persistent and relapsing infections associated with small-colony variants of *Staphylococcus aureus*. *Clin. Infect. Dis.* 20, 95–102.
- Proctor, R.A., von Eiff, C., Kahl, B.C., Becker, K., McNamara, P., Herrmann, M., Peters, G., 2006. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. *Nat. Rev. Microbiol.* 4, 295–305.
- Reilly, S.S., Hudson, M.C., Kellam, J.F., Ramp, W.K., 2000. In vivo internalization of *Staphylococcus aureus* by embryonic chick osteoblasts. *Bone* 26, 63–70.
- Reott Jr., M.A., Ritchie-Miller, S.L., Anguita, J., Hudson, M.C., 2008. TRAIL expression is induced in both osteoblasts containing intracellular *Staphylococcus aureus* and uninfected osteoblasts in infected cultures. *FEMS Microbiol. Lett.* 278, 185–192.
- Robinson, L.J., Borysenko, C.W., Blair, H.C., 2007. Tumor necrosis factor family receptors regulating bone turnover: new observations in osteoblastic and osteoclastic cell lines. *Ann. NY Acad. Sci.* 1116, 432–443.
- Rodig, S.J., Meraz, M.A., White, J.M., Lampe, P.A., Riley, J.K., Arthur, C.D., King, K.L., Sheehan, K.C., Yin, L., Pennica, D., Johnson Jr., E.M., Schreiber, R.D., 1998. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biological responses. *Cell* 93, 373–383.
- Ryan, M.J., Kavanagh, R., Wall, P.G., Hazleman, B.L., 1997. Bacterial joint infections in England and Wales: analysis of bacterial isolates over a four year period. *Br. J. Rheumatol.* 36, 370–373.
- Saez-Llorens, X., Mustafa, M.M., Ramilo, O., Fink, C., Beutler, B., Nelson, J.D., 1990. Tumor necrosis factor alpha and interleukin 1 beta in synovial fluid of infants and children with suppurative arthritis. *Am. J. Dis. Child.* 144, 353–356.
- Salo, J., Lehenkari, P., Mulari, M., Metsikko, K., Vaananen, H.K., 1997. Removal of osteoclast bone resorption products by transcytosis. *Science* 276, 270–273.
- Sdougkos, G., Chini, V., Papanastasiou, D.A., Christodoulou, G., Tagaris, G., Dimitracopoulos, G., Spiliopoulou, I., 2007. Methicillin-resistant *Staphylococcus aureus* producing Pantone-Valentine leukocidin as a cause of acute osteomyelitis in children. *Clin. Microbiol. Infect.* 13, 651–654.
- Seifert, H., Oltmanns, D., Becker, K., Wisplinghoff, H., von, E.C., 2005. *Staphylococcus lugdunensis* pacemaker-related infection. *Emerg. Infect. Dis.* 11, 1283–1286.
- Sendi, P., Proctor, R.A., 2009. *Staphylococcus aureus* as an intracellular pathogen: the role of small colony variants. *Trends Microbiol.* 17, 54–58.
- Sendi, P., Rohrbach, M., Graber, P., Frei, R., Ochsner, P.E., Zimmerli, W., 2006. *Staphylococcus aureus* small colony variants in prosthetic joint infection. *Clin. Infect. Dis.* 43, 961–967.
- Shaw, L.N., Lindholm, C., Prajsnar, T.K., Miller, H.K., Brown, M.C., Golonka, E., Stewart, G.C., Tarkowski, A., Potempa, J., 2008. Identification and characterization of sigma, a novel component of the *Staphylococcus aureus* stress and virulence responses. *PLoS One* 3, e3844.
- Shirliff, M.E., Mader, J.T., 2002. Acute septic arthritis. *Clin. Microbiol. Rev.* 15, 527–544.
- Sinha, B., Francois, P.P., Nusse, O., Foti, M., Hartford, O.M., Vaudaux, P., Foster, T.J., Lew, D.P., Herrmann, M., Krause, K.H., 1999. Fibronectin-binding protein acts as *Staphylococcus aureus* invasin via fibronectin bridging to integrin alpha5beta1. *Cell. Microbiol.* 1, 101–117.
- Smith, D.D., Gowen, M., Mundy, G.R., 1987. Effects of interferon-gamma and other cytokines on collagen synthesis in fetal rat bone cultures. *Endocrinology* 120, 2494–2499.
- Stapleton, M.R., Horsburgh, M.J., Hayhurst, E.J., Wright, L., Jonsson, I.M., Tarkowski, A., Kokai-Kun, J.F., Mond, J.J., Foster, S.J., 2007. Characterization of IsaA and Sced, two putative lytic transglycosylases of *Staphylococcus aureus*. *J. Bacteriol.* 189, 7316–7325.
- Stoodley, P., Nistico, L., Johnson, S., Lasko, L.A., Baratz, M., Gahlot, V., Ehrlich, G.D., Kathju, S., 2008. Direct demonstration of viable *Staphylococcus aureus* biofilms in an infected total joint arthroplasty. A case report. *J. Bone Joint Surg. Am.* 90, 1751–1758.
- Stott, N.S., 2001. Paediatric bone and joint infection. *J. Orthop. Surg. (Hong Kong)* 9, 83–90.
- Takeuchi, O., Hoshino, K., Kawai, T., Sanjo, H., Takada, H., Ogawa, T., Takeda, K., Akira, S., 1999. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. *Immunity* 11, 443–451.
- Takeuchi, O., Hoshino, K., Akira, S., 2000. Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to *Staphylococcus aureus* infection. *J. Immunol.* 165, 5392–5396.
- Tarkowski, A., Collins, L.V., Gjerdtsson, I., Hultgren, O.H., Jonsson, I.M., Sakiniene, E., Verdrehn, M., 2001. Model systems: modeling human staphylococcal arthritis and sepsis in the mouse. *Trends Microbiol.* 9, 321–326.
- Taubman, M.A., Kawai, T., 2001. Involvement of T-lymphocytes in periodontal disease and in direct and indirect induction of bone resorption. *Crit. Rev. Oral Biol. Med.* 12, 125–135.
- Thomson, B.M., Mundy, G.R., Chambers, T.J., 1987. Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. *J. Immunol.* 138, 775–779.
- Ting, J.P.Y., Willingham, S.B., Bergstralh, D.T., 2008. NLRs at the intersection of cell death and immunity. *Nat. Rev. Immunol.* 8, 372–379.
- Tokukoda, Y., Takata, S., Kaji, H., Kitazawa, R., Sugimoto, T., Chihara, K., 2001. Interleukin-1beta stimulates transendothelial mobilization of human peripheral blood mononuclear cells with a potential to differentiate into osteoclasts in the presence of osteoblasts. *Endocr. J.* 48, 443–452.
- Tsezou, A., Poultsides, L., Kostopoulou, F., Zintzaras, E., Satra, M., Kitsiou-Tzeli, S., Malizos, K.N., 2008. Influence of interleukin 1alpha (IL-1alpha), IL-4, and IL-6 polymorphisms on genetic susceptibility to chronic osteomyelitis. *Clin. Vaccine Immunol.* 15, 1888–1890.
- Tucker, K.A., Reilly, S.S., Leslie, C.S., Hudson, M.C., 2000. Intracellular *Staphylococcus aureus* induces apoptosis in mouse osteoblasts. *FEMS Microbiol. Lett.* 186, 151–156.
- U.K. Health Protection Agency, 2008. Surgical Site Infection – National aggregated data on Surgical Site Infections for hospitals that have participated in Surgical Site Infection Surveillance Scheme (SSISS) between October 1997 and December 2005. <<http://www.hpa.org.uk/HPA/Topics/InfectiousDiseases/InfectionsAZ/1202115536296/>>.
- Udagawa, N., Takahashi, N., Katagiri, T., Tamura, T., Wada, S., Findlay, D.M., Martin, T.J., Hirota, H., Taga, T., Kishimoto, T., Suda, T., 1995. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. *J. Exp. Med.* 182, 1461–1468.
- Vaananen, H.K., Laitala-Leinonen, T., 2008. Osteoclast lineage and function. *Arch. Biochem. Biophys.* 473, 132–138.
- Vallianou, N., Evangelopoulos, A., Makri, P., Zacharias, G., Stefanitsi, P., Karachalios, A., Avgerinos, P.C., 2008. Vertebral osteomyelitis and native valve endocarditis due to *Staphylococcus simulans*: a case report. *J. Med. Case Reports* 2, 183.
- van de Lest, C.H., Vaandrager, A.B., 2007. Mechanism of cell-mediated mineralization. *Curr. Opin. Orthop.* 18, 434–443.
- Vaudaux, P., Francois, P., Bisognano, C., Kelley, W.L., Lew, D.P., Schrenzel, J., Proctor, R.A., McNamara, P.J., Peters, G., von Eiff, C., 2002. Increased expression of clumping factor and fibronectin-binding proteins by *hemB* mutants of *Staphylococcus aureus* expressing small colony variant phenotypes. *Infect. Immun.* 70, 5428–5437.
- Verstrepen, L., Bekaert, T., Chau, T.L., Tavernier, J., Chariot, A., Beyaert, R., 2008. TLR-4, IL-1R and TNF-R signaling to NF-kappaB: variations on a common theme. *Cell. Mol. Life Sci.* 65, 2964–2978.
- von Eiff, C., 2008. *Staphylococcus aureus* small colony variants: a challenge to microbiologists and clinicians. *Int. J. Antimicrob. Agents* 31, 507–510.
- von Eiff, C., Bettin, D., Proctor, R.A., Rolauffs, B., Lindner, N., Winkelmann, W., Peters, G., 1997a. Recovery of small colony variants of *Staphylococcus aureus* following gentamicin bead placement for osteomyelitis. *Clin. Infect. Dis.* 25, 1250–1251.
- von Eiff, C., Heilmann, C., Proctor, R.A., Woltz, C., Peters, G., Gotz, F., 1997b. A site-directed *Staphylococcus aureus hemB* mutant is a small-colony variant which persists intracellularly. *J. Bacteriol.* 179, 4706–4712.
- von Eiff, C., Vaudaux, P., Kahl, B.C., Lew, D., Emler, S., Schmidt, A., Peters, G., Proctor, R.A., 1999. Bloodstream infections caused by small-colony variants of coagulase-negative staphylococci following pacemaker implantation. *Clin. Infect. Dis.* 29, 932–934.
- von Eiff, C., Becker, K., Metz, D., Lubritz, G., Hockmann, J., Schwarz, T., Peters, G., 2001. Intracellular persistence of *Staphylococcus aureus* small-colony variants within keratinocytes: a cause for antibiotic treatment failure in a patient with Darier's disease. *Clin. Infect. Dis.* 32, 1643–1647.
- von Eiff, C., Peters, G., Becker, K., 2006. The small colony variant (SCV) concept – the role of staphylococcal SCVs in persistent infections. *Injury* 37 (Suppl. 2), S26–S33.
- Wada, T., Nakashima, T., Hiroshi, N., Penninger, J.M., 2006. RANKL-RANK signaling in osteoclastogenesis and bone disease. *Trends Mol. Med.* 12, 17–25.
- Wajant, H., Pfizenmaier, K., Scheurich, P., 2003. Tumor necrosis factor signaling. *Cell Death Differ.* 10, 45–65.
- Wang, B., Yurecko, R.S., Dedhar, S., Cleary, P.P., 2006. Integrin-linked kinase is an essential link between integrins and uptake of bacterial pathogens by epithelial cells. *Cell. Microbiol.* 8, 257–266.
- Weichert, S., Sharland, M., Clarke, N.M., Faust, S.N., 2008. Acute haematogenous osteomyelitis in children: is there any evidence for how long we should treat? *Curr. Opin. Infect. Dis.* 21, 258–262.
- Xing, L., Carlson, L., Story, B., Tai, Z., Keng, P., Siebenlist, U., Boyce, B.F., 2003. Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. *J. Bone Miner. Res.* 18, 260–269.
- Xu, Y., Rivas, J.M., Brown, E.L., Liang, X., Hook, M., 2004. Virulence potential of the staphylococcal adhesin CNA in experimental arthritis is determined by its affinity for collagen. *J. Infect. Dis.* 189, 2323–2333.
- Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N., Suda, T., 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. *Proc. Natl. Acad. Sci. USA* 95, 3597–3602.
- Yoshii, T., Magara, S., Miyai, D., Nishimura, H., Kuroki, E., Furudoi, S., Komori, T., Ohbayashi, C., 2002. Local levels of interleukin-1beta, -4, -6 and tumor necrosis factor alpha in an experimental model of murine osteomyelitis due to *Staphylococcus aureus*. *Cytokine* 19, 59–65.
- Zauli, G., Rimondi, E., Nicolin, V., Melloni, E., Celeghini, C., Secchiero, P., 2004. TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. *Blood* 104, 2044–2050.
- Zou, W., Hakim, I., Tschoep, K., Endres, S., Bar-Shavit, Z., 2001. Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. *J. Cell. Biochem.* 83, 70–83.